Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Follow-up Registration Management of Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer

NCT05383066 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT05383066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05383066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Follow-up Registration Management of Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer
Lead sponsor
Peking University First Hospital
Phase
Observational
Overall status
Unknown status
Start date
May 20, 2022
Completion date
December 30, 2024
Enrollment
490 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular